Delhi: IHH Healthcare, a prominent global healthcare provider, has escalated its legal battle with Japan's Daiichi Sankyo, ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid ...

IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...

KUALA LUMPUR, Feb 7 (Bernama) -- IHH Healthcare Bhd’s share price on Bursa Malaysia edged higher in early trading after its unit Northern TK Venture Pte Ltd (NTK) sought compensation from Japan’s ...

IHH Healthcare said on Thursday its unit submitted an expert report to a Tokyo court which states damages sought from Japan's ...

IHH Healthcare Bhd’s share price on Bursa Malaysia edged higher in early trading after its unit Northern TK Venture Pte Ltd ...

Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 10.05%, which has investors questioning if this is right time to ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

IHH Healthcare Bhd says its unit is seeking compensation of up to 109.3 billion rupees (RM5.46bil) from Japan’s Daiichi Sankyo for its stake buy in India’s Fortis Healthcare.

Malaysia’s IHH Healthcare is seeking up to Rs 10,930 crore ($1.25 billion) in damages from Japan’s Daiichi Sankyo for its involvement in Fortis Healt ...